Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2025

Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2025

Summary

GlobalData's clinical trial report, “Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2025" - provides an overview of Duchenne Muscular Dystrophy Clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

    – The report provides a snapshot of the global clinical trials landscape– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment– The Report provides enrollment trends for the past five years– Report provides latest news for the past three months
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Duchenne Muscular Dystrophy Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Duchenne Muscular Dystrophy
Mar 31, 2025: Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
Mar 27, 2025: Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531
Mar 19, 2025: Precision Biosciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of DMD at the 2025 MDA
Mar 19, 2025: FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
Mar 19, 2025: Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Mar 17, 2025: Roche to Share Latest Scientific Advancements From Its Neuromuscular Portfolio at Muscular Dystrophy Association 2025 Conference
Mar 17, 2025: ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference
Mar 17, 2025: Capricor Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Mar 10, 2025: PepGen Announces Presentation on PGNEDODM-1 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Mar 10, 2025: PepGen Announces Presentation on PGNEDO-51 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Mar 04, 2025: Pepgen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients With DMD
Feb 24, 2025: Precision Biosciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Feb 24, 2025: Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Feb 21, 2025: Scholar Rock To Present Additional Clinical Data From the Phase 3 Sapphire Trial at the 2025 MDA Clinical & Scientific Conference
Feb 18, 2025: Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Feb 12, 2025: Percheron Makes Rapid Progress in Partnering Discussions; Initial Proposals Expected to Be Submitted in February 2025
Feb 11, 2025: Satellos concludes MAD cohort enrolment for Phase I trial of SAT-3247
Feb 05, 2025: Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD
Jan 29, 2025: PepGen Announces CONNECT Program Updates
Jan 28, 2025: Roche reports positive topline outcomes from DMD treatment trial
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source
List of Tables
Table 1: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2025*
Table 2: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Table 3: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Table 4: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
Table 5: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
Table 6: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries, 2025*
Table 7: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
Table 8: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
Table 9: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2025*
Table 10: Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Table 11: Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Table 12: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2025*
Table 13: Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Table 14: Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Table 15: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase, 2025*
Table 16: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
Table 17: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Table 18: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Table 19: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Table 20: Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
Table 21: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Table 22: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Table 23: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
List of Figures
Figure 1: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2025*
Figure 2: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Figure 3: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Figure 4: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
Figure 5: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
Figure 6: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
Figure 7: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
Figure 8: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
Figure 9: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2025*
Figure 10: Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Figure 11: Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Figure 12: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2025*
Figure 13: Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Figure 14: Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Figure 15: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2025*
Figure 16: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
Figure 17: Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Figure 18: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Figure 19: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Figure 20: Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
Figure 21: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Figure 22: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Figure 23: Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
Figure 24: GlobalData Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings